No Data
No Data
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of Anti-IL-17A/F VHH Antibodies
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Shares Are Trading Higher After the Company Announced It Regained Compliance With the Nasdaq.
Scinai Regains Full Compliance With Nasdaq Listing Requirements
Scinai Immunotherapeutics Restructures Debt, Boosts Equity
Press Release: Scinai Announces Closing of Loan Restructuring Agreement With European Investment Bank Converting Approximately $29 Million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
No Data
No Data